AstraZeneca Q2 Non-GAAP Earnings Exceed Expectations
In the second quarter, AstraZeneca reported a non-GAAP earnings per share (EPS) of $2.63, surpassing expectations by $1.36 and signaling strong performance despite revenue falling slightly short. The company's Q2 revenue came in at $15.38 billion, representing a 6.4% year-over-year increase but missing estimates by $50 million. AstraZeneca also announced an interim dividend of $1.06 per share, up from the previous level. The pharmaceutical giant reaffirmed its full-year outlook for FY2026, projecting revenue growth of approximately 7.6%. This guidance reflects confidence in maintaining momentum despite challenges such as pricing pressures and regulatory hurdles across key markets.
Tickers: $AZN
Topics: financial_results pharmaceuticals